Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments
ResMed Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 21.1% to $78.47M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.0%, from $65.38M to $78.47M. Over 4 years (FY 2021 to FY 2025), Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments shows an upward trend with a 29.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase indicates deteriorating performance or valuation write-downs in the private equity or venture portfolio.
Detailed definition
The cumulative amount of downward fair value adjustments recognized for equity securities that lack a readily determinab...
Peer comparison
Standard for firms with significant private equity or venture capital exposure.
equity_securities_no_fv_downward_adjHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.00M | $31.16M | $35.18M | $38.18M | $39.29M | $43.58M | $65.70M | $70.64M | $68.75M | $69.68M | $74.99M | $77.38M | $73.74M | $65.78M | $66.46M | $65.38M | $63.64M | $64.53M | $64.78M | $78.47M |
| QoQ Change | — | +35.5% | +12.9% | +8.5% | +2.9% | +10.9% | +50.7% | +7.5% | -2.7% | +1.4% | +7.6% | +3.2% | -4.7% | -10.8% | +1.0% | -1.6% | -2.7% | +1.4% | +0.4% | +21.1% |
| YoY Change | — | — | — | — | +70.8% | +39.9% | +86.7% | +85.0% | +75.0% | +59.9% | +14.1% | +9.5% | +7.3% | -5.6% | -11.4% | -15.5% | -13.7% | -1.9% | -2.5% | +20.0% |
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at Other Companies
Frequently Asked Questions
- What is ResMed's equity securities without readily determinable fair value - cumulative downward adjustments?
- ResMed (RMD) reported equity securities without readily determinable fair value - cumulative downward adjustments of $78.47M in Q1 2026.
- How has ResMed's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
- ResMed's equity securities without readily determinable fair value - cumulative downward adjustments increased by 20.0% year-over-year, from $65.38M to $78.47M.
- What is the long-term trend for ResMed's equity securities without readily determinable fair value - cumulative downward adjustments?
- Over 4 years (2021 to 2025), ResMed's equity securities without readily determinable fair value - cumulative downward adjustments has grown at a 29.0% compound annual growth rate (CAGR), from $23.00M to $63.64M.
- What does equity securities without readily determinable fair value - cumulative downward adjustments mean?
- Total value lost on private or hard-to-value equity investments.